tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2022-100-11-56-65tiblj-1693Research ArticleОБЗОРREVIEWБезопасность химиотерапии у больных МЛУ/ШЛУ-ТБ в условиях широкой распространенности ВИЧ-инфекцииSafety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settingsКукурикаА. В.KukurikaA. V.

Кукурика Анастасия Владимировна, специалист по учебно-методической работе Центра образования

127473, Москва, ул. Достоевского, д. 4 к. 2

Anastasia V. Kukurika, Specialist in Educational and Methodical Activities of Education Center

Build. 2, 4, Dostoevskiy St., Moscow, 127473

nastya_kukurika@mail.ruВеселоваЕ. И.VeselovaE. I.

Веселова Елена Игоревна, научный сотрудник научного отдела инфекционной патологии

127473, Москва, ул. Достоевского, д. 4 к. 2

Elena I. Veselova, Researcher of Infectious Pathology Research Department

Build. 2, 4, Dostoevskiy St., Moscow, 127473

drveselovae@mail.ruПаролинаЛ. Е.ParolinaL. E.

Паролина Любовь Евгеньевна, доктор медицинских наук, профессор, руководитель Центра образования, профессор кафедры фтизиатрии ЛФ

117997, Москва, ул. Островитянова, д. 1, стр. 7

Lyubov E. Parolina, Doctor of Medical Sciences, Professor, Head of Education Center

1, Bd. 7, Ostrovityanova St., Moscow, 117997

ParolinaLE@nmrc.ruЛовачеваО. В.LovachevaO. V.

Ловачева Ольга Викторовна, доктор медицинских наук, профессор, главный научный сотрудник, профессор кафедры фтизиатрии

125993, г. Москва, ул. Баррикадная, д. 2/1, стр. 1

Olga V. Lovacheva, Doctor of Medical Sciences, Professor, Chief Researcher

2/1, Build. 1. Barrikadnaya St., Moscow, 125993

olga.lovacheva@yandex.ruФГБУ «Научный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» МЗ РФ; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases; Pirogov Russian National Research Medical UniversityRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ; ФГБУ «Научный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases; Russian Medical Academy of On-going Professional EducationRussian Federation202209122022100115665Copyright © Кукурика А.В., Веселова Е.И., Паролина Л.Е., Ловачева О.В., 20222022Кукурика А.В., Веселова Е.И., Паролина Л.Е., Ловачева О.В.Kukurika A.V., Veselova E.I., Parolina L.E., Lovacheva O.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1693

В обзоре использован 61 литературный источник для обсуждения 13 публикаций, посвященных проблеме безопасности лечения ВИЧ-ассоциированного лекарственно-устойчивого туберкулеза с применением базовых и новых режимов химиотерапии. Согласно данным литературы, аддитивного токсического действия на фоне лечения противотуберкулезными и антиретровирусными препаратами не выявлено. В условиях широкой распространенности ВИЧ особо актуальным является фармаконадзор за лекарственным взаимодействием комбинированной терапии, поскольку ВИЧ может косвенно увеличить количество нежелательных реакций (НР) не только из-за перекрестной токсичности, но и выраженной иммуносупрессии, развития синдрома восстановления иммунной системы, оппортунистических инфекций, характерного интоксикационного синдрома, низкого индекса массы тела и индивидуальных особенностей больных.

The review used 61 literature sources to discuss 13 publications devoted to safety of treatment of HIV-associated drug-resistant tuberculosis using basic and new regimens of chemotherapy. According to the literature, no additive toxic effects were detected during treatment with anti-tuberculosis and antiretroviral drugs. According to the literature data, no additive toxic effect was found during treatment with anti-tuberculosis and antiretroviral drugs. In conditions of high prevalence of HIV, the pharmacovigilance of drug interactions in combination therapy is particularly relevant since HIV can indirectly increase the number of ADRs not only due to cross-toxicity but also severe immunosuppression, development of immune system recovery syndrome, opportunistic infections, a characteristic intoxication syndrome, a low index body weight and individual characteristics of patients in this category.

МЛУ/ШЛУ-ТБВИЧбезопасностьнежелательные побочные реакциипротивотуберкулезные препаратыантиретровирусная терапиясхемы леченияMDR/XDR-TBHIVsafetyadverse eventsanti-TB drugsantiretroviral therapytreatment regimensReferencesБорисов С. Е., Филиппов А. В., Иванова Д. А., Иванушкина Т. Н., Литвинова Н. В., Гармаш Ю. Ю. Эффективность и безопасность основанных на использовании бедаквилина режимов химиотерапии у больных туберкулезом органов дыхания: непосредственные и окончательные результаты // Туб. и болезни легких. – 2019. – Т. 97, № 5. – С. 28-40. http://doi.org/10.21292/2075-1230-2019-97-5-28-40.Borisov S.E., Filippov A.V., Ivanova D.A., Ivanushkina T.N., Litvinova N.V., Garmash Yu.Yu. Efficacy and safety of chemotherapy regimens containing bedaquiline in respiratory tuberculosis patients: immediate and final results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 5, pp. 28-40. (In Russ.) http://doi.org/10.21292/2075-1230-2019-97-5-28-40.Гайда А. И., Свешникова О. М., Верховая В. Н., Махмаева С. В., НикишоваЕ. И., Марьяндышев А. О. Лечение больных туберкулезом с широкой лекарственной устойчивостью микобактерий с применением новых противотуберкулезных препаратов в гражданском обществе Архангельской области // Туб. и болезни легких. – 2018. – Т. 96, № 7. – С. 5-10. DOI: 10.21292/2075-1230-2018-96-7-5-10.Gayda A.I., Sveshnikova O.M., Verkhovaya V.N., Makhmaeva S.V., Nikishova E.I., Maryandyshev A.O. Treatment of tuberculosis patients with extensive drug resistance using new anti-tuberculosis drugs in the civilian community of Arkhangelsk Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 7, pp. 5-10. (In Russ.) doi: 10.21292/2075-1230-2018-96-7-5-10.Данилова Т. И., Корнеев Ю. В., Кудлай Д. А., Николенко Н. Ю. Результаты применения схем терапии на основе бедаквилина у больных туберкулезом с МЛУ/ШЛУ, в том числе при сочетании с ВИЧ-инфекцией (опыт Ленинградской области) // Туб. и болезни легких. – 2020. – Т. 98, № 9. – С. 56-62. http://doi.org/10.21292/2075-1230-2020-98-9-56-62.Danilova T.I., Korneev Yu.V., Kudlai D.A., Nikolenko N.Yu. Results of treatment with bedaquiline containing regimens of MDR/XDR tuberculosis patients including those with concurrent HIV infection (the experience of Leningrad Region). Tuberculosis and Lung Diseases, 2020, vol. 98, no. 9, pp. 56-62. (InRuss.) http://doi.org/10.21292/2075-1230-2020-98-9-56-62.Дегтярева С. Ю., Белобородова Е. Н., Покровская А. В., КлимоваЮ.А., Викторова И. Б., Зимина В. Н. Безопасность терапии туберкулеза с множественной лекарственной устойчивостью возбудителя у больных ВИЧ-инфекцией, получающих антиретровирусную терапию // Туб. и болезни легких. – 2019.– Т. 97, № 3. – С. 46-53. http://doi.org/10.21292/2075-1230-2019-97-3-46-53.Degtyareva S.Yu., Beloborodova E.N., Pokrovskaya A.V., Klimova Yu.A., Viktorova I.B., Zimina V.N. The safety of treatment of multiple drug resistant tuberculosis in HIV positive patients receiving antiretroviral therapy. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 3, pp. 46-53. (In Russ.) http://doi.org/10.21292/2075-1230-2019-97-3-46-53.Жукова Е. М., Вохминова Л. Г., Кудлай Д. А. Влияние современной химиотерапии туберкулеза с МЛУ/ШЛУ на изменение у больных интервала QT на ЭКГ // Туб. и болезни легких. ‒ 2019. ‒ Т. 97, № 11. ‒ С. 19-22. http://doi.org/10.21292/2075-1230-2019-97-11-19-22.Zhukova E.M., Vokhminova L.G., Kudlay D.A. The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 11, pp. 19-22. (In Russ.) http://doi.org/10.21292/2075-130-2019-97-11-19-22.Зимина В. Н., Микова О. Е., Варецкая Т. А., Оборин Д. А., ДегтяреваС.Ю., Сергевнин В. И. Спектр первичной устойчивости Mycobacterium tuberculosis к лекарствам у больных туберкулезом в зависимости от статуса по вирусу иммунодефицита человека // Терапевтический архив. ‒ 2017.‒ Т. 89, № 11. ‒ С. 50-54.Zimina V.N., Mikova O.E., Varetskaya T.A., Oborin D.A., Degtyareva S.Yu., Sergevnin V.I. The pattern of primary drug resistance of Mycobacterium tuberculosis in tuberculosis patients depending on HIV status. Terapevticheskiy Arkhiv, 2017, vol. 89, no. 11, pp. 50- 54. (In Russ.)Иванова Д. А., Борисов С. Е., Родина О. В., Филиппов А. В., ИванушкинаТ.Н., Литвинова Н. В. Безопасность режимов лечения больных туберкулезом с множественной лекарственной устойчивостью возбудителя согласно новым рекомендациям ВОЗ 2019 г. // Туб. и болезни легких. – 2020.– Т.98, № 1. – С. 5-15. http://doi.org/10.21292/2075-1230-2020-98-1-5-15.Ivanova D.A., Borisov S.E., Rodina O.V., Filippov A.V., Ivanushkina T.N., Litvinova N.V. Safety of treatment regimens for multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 1, pp. 5-15. (In Russ.) http://doi.org/10.21292/2075-1230-2020-98-1-5-15.Наумов А. Г., Павлунин А. В. Перспективы применения таргетной химиотерапии деламанидом в схемах лечения больных туберкулезом с множественной/широкой лекарственной устойчивостью возбудителя. Успехи, возможности или неопределенность? // Туб. и болезни легких. ‒ 2018. ‒ Т.96, № 11. ‒ С. 74-82. DOI: 10.21292/2075-1230-2018-96-11-74-82.Naumov A.G., Pavlunin A.V. Perspectives of targeted chemotherapy with delamanid in the treatment regimens of those with multiple/extensive drug resistant tuberculosis. A success, chance or uncertainty? Tuberculosis and Lung Diseases, 2018, vol. 96, no. 11, pp. 74-82. (In Russ.) doi: 10.21292/2075-1230-2018-96-11-74-82.Попов С. А., Сабгайда Т. П., Радина Т. С. Оценка взаимосвязи ВИЧ-инфекции и туберкулеза с множественной лекарственной устойчивостью возбудителя // Туб. и болезни легких. ‒ 2018. ‒ Т. 96, № 7. ‒ С. 25-32. https://doi.org/10.21292/2075-1230-2018-96-7-25-32.Popov S.A., Sabgayda T.P., Radina T.S. Assessment of correlation between HIV infection and tuberculosis with multiple drug resistance. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 7, pp. 25-32. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-7-25-32.Щегерцов Д. Ю., Филинюк О. В., Буйнова Л. Н., Земляная Н. А., КабанецН. Н., Аллилуев А. С. Нежелательные побочные реакции при лечении больных туберкулезом с множественной лекарственной устойчивостью возбудителя // Туб. и болезни легких. – 2018. – Т. 96, № 3. – С. 35-43. DOI: 10.21292/2075-1230-2018-96-3-35-43.Schegertsov D.Yu., Filinyuk O.V., Buynova L.N., Zemlyanaya N.A., KabanetsN.N., Alliluyev A.S. Adverse events during treatment of patients suffering from multiple drug resistant tuberculosis. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 3, pp. 35-43. (In Russ.) doi: 10.21292/2075-1230-2018-96-3-35-43.Agyeman A. A., Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis // Ann. Clin. Microbiol. Antimicrob. ‒ 2016. ‒ Vol. 15, № 1. ‒ Р. 41. doi: 10.1186/s12941-016-0156-y.Agyeman A.A., Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann. Clin. Microbiol. Antimicrob., 2016, vol. 15, no. 1, pp. 41. doi: 10.1186/s12941-016-0156-y.Auld S. C., Staitieh B. S. HIV and the tuberculosis "set point": how HIV impairs alveolar macrophage responses to tuberculosis and sets the stage for progressive disease // Retrovirology. ‒ 2020. ‒ Vol. 17, № 1. ‒ Р. 32. doi: 10.1186/s12977-020-00540-2.Auld S.C., Staitieh B.S. HIV and the tuberculosis "set point": how HIV impairs alveolar macrophage responses to tuberculosis and sets the stage for progressive disease. Retrovirology, 2020, vol. 17, no. 1, pp. 32. doi: 10.1186/s12977-020-00540-2.Avaliani T., Sereda Y., Davtyan H., Tukvadze N., Togonidze T., Kiria N., DenisiukO., Gozalov O., Ahmedov S., Hovhannesyan A. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020 // Monaldi Arch Chest Dis. ‒ 2021. ‒ Vol. 91, № 1. doi: 10.4081/monaldi.2021.1679.Avaliani T., Sereda Y., Davtyan H., Tukvadze N., Togonidze T., Kiria N., DenisiukO., Gozalov O., Ahmedov S., Hovhannesyan A. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020. Monaldi Arch Chest Dis., 2021, vol. 91, no. 1. doi: 10.4081/monaldi.2021.1679.Baluku J. B., Mugabe P., Mulwana R., Nassozi S., Katuramu R., Worodria W. High prevalence of rifampicin resistance associated with rural residence and very low bacillary load among TB/HIV-coinfected patients at the National Tuberculosis Treatment Center in Uganda // Biomed. Res. Int. ‒ 2020;2020:2508283. doi: 10.1155/2020/2508283.Baluku J.B., Mugabe P., Mulwana R., Nassozi S., Katuramu R., Worodria W. High prevalence of rifampicin resistance associated with rural residence and very low bacillary load among TB/HIV-coinfected patients at the National Tuberculosis Treatment Center in Uganda. Biomed. Res. Int., 2020;2020:2508283. doi: 10.1155/2020/2508283.Bhering M., Duarte R., Kritski A. Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil // Int. J. Tuberc. Lung Dis. ‒ 2021. ‒ Vol. 25, № 4. ‒ Р. 292-298. doi: 10.5588/ijtld.20.0887.Bhering M., Duarte R., Kritski A. Treatment outcomes and predictive factors for multidrug-resistant TB and HIV coinfection in Rio de Janeiro State, Brazil. Int. J. Tuberc. Lung Dis., 2021, vol. 25, no. 4, pp. 292-298. doi: 10.5588/ijtld.20.0887.Borisov S., Danila E., Maryandyshev A., Dalcolmo M., Miliauskas S., KuksaL., Manga S., Skrahina A., Diktanas S., Codecasa L. R., Aleksa A., BruchfeldJ., KolevaA., Piubello A., Udwadia Z. F., Akkerman O. W., Belilovski E., BernalE., BoereeM.J., Cadiñanos Loidi J., Cai Q., Cebrian Gallardo J. J., Dara M., Davidavičienė E., Forsman L. D., De Los Rios J., Denholm J., DrakšienėJ., Duarte R., ElaminS. E., Escobar Salinas N., Ferrarese M., Filippov A., GarciaA., García-García J. M., Gaudiesiute I., Gavazova B., Gayoso R., Gomez RossoR., Gruslys V., Gualano G., Hoefsloot W., Jonsson J., Khimova E., Kunst H., Laniado-Laborín R., LiY., Magis-Escurra C., Manfrin V., Marchese V., Martínez Robles E., Matteelli A., Mazza-Stalder J., Moschos C., Muñoz-Torrico M., Mustafa Hamdan H., Nakčerienė B., Nicod L., Nieto Marcos M., PalmeroD.J., PalmieriF., Papavasileiou A., Payen M. C., Pontarelli A., Quirós S., RendonA., Saderi L., ŠmiteA., Solovic I., Souleymane M. B., Tadolini M., van den Boom M., VescovoM., Viggiani P., Yedilbayev A., Zablockis R., Zhurkin D., Zignol M., ViscaD., Spanevello A., Caminero J. A., Alffenaar J. W., TiberiS., Centis R., D'AmbrosioL., Pontali E., Sotgiu G., Migliori G. B. Jain N. K. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report // Eur. Respir. J. ‒ 2019. ‒ Vol. 54, № 6. ‒ Р. 1901522. doi: 10.1183/13993003.01522-2019.Borisov S., Danila E., Maryandyshev A., Dalcolmo M., Miliauskas S., KuksaL., Manga S., Skrahina A., Diktanas S., Codecasa L.R., Aleksa A., BruchfeldJ., KolevaA., Piubello A., Udwadia Z.F., Akkerman O.W., BelilovskiE., BernalE., Boeree M.J., Cadiñanos Loidi J., Cai Q., Cebrian Gallardo J.J., Dara M., Davidavičienė E., Forsman L.D., De Los Rios J., Denholm J., Drakšienė J., Duarte R., Elamin S.E., Escobar Salinas N., Ferrarese M., Filippov A., GarciaA., García-García J.M., Gaudiesiute I., Gavazova B., Gayoso R., Gomez RossoR., Gruslys V., Gualano G., Hoefsloot W., Jonsson J., Khimova E., Kunst H., Laniado-Laborín R., Li Y., Magis-Escurra C., Manfrin V., Marchese V., Martínez Robles E., Matteelli A., Mazza-Stalder J., Moschos C., Muñoz-Torrico M., Mustafa Hamdan H., Nakčerienė B., Nicod L., Nieto Marcos M., PalmeroD.J., PalmieriF., Papavasileiou A., Payen M.C., Pontarelli A., Quirós S., RendonA., Saderi L., Šmite A., Solovic I., Souleymane M.B., Tadolini M., van den Boom M., VescovoM., Viggiani P., Yedilbayev A., Zablockis R., Zhurkin D., Zignol M., Visca D., Spanevello A., Caminero J.A., Alffenaar J.W., TiberiS., Centis R., D'Ambrosio L., Pontali E., Sotgiu G., Migliori G.B., Jain N.K. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur. Respir. J., 2019, vol. 54, no. 6, pp. 1901522. doi: 10.1183/13993003.01522-2019.Brust J. C., Shah N. S., van der Merwe T. L., Bamber S., Ning Y., Heo M., MollA.P., Loveday M., Lalloo U. G., Friedland G. H., Gandhi N. R. Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa // J. Acquir. Immune Defic. Syndr. ‒ 2013. ‒ Vol. 62, № 4. ‒ Р. 436-440. doi: 10.1097/QAI.0b013e31828175ed.Brust J.C., Shah N.S., van der Merwe T.L., Bamber S., Ning Y., Heo M., MollA.P., Loveday M., Lalloo U.G., Friedland G.H., Gandhi N.R. Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. J. Acquir. Immune Defic. Syndr., 2013, vol. 62, no. 4, pp. 436-440. doi: 10.1097/QAI.0b013e31828175ed.Brust J. C. M., Shah N. S., Mlisana K., Moodley P., Allana S., CampbellA., Johnson B. A., Master I., Mthiyane T., Lachman S., Larkan L. M., Ning Y., Malik A., Smith J. P., Gandhi N. R. Improved survival and cure rates with concurrent treatment for multidrug-resistant tuberculosis-human immunodeficiency virus coinfection in South Africa // Clin. Infect. Dis. ‒ 2018.‒ Vol. 66, № 8. ‒ Р. 1246-1253. doi: 10.1093/cid/cix1125.Brust J.C.M., Shah N.S., Mlisana K., Moodley P., Allana S., Campbell A., JohnsonB.A., Master I., Mthiyane T., Lachman S., Larkan L.M., Ning Y., MalikA., Smith J.P., Gandhi N.R. Improved survival and cure rates with concurrent treatment for multidrug-resistant tuberculosis-human immunodeficiency virus coinfection in South Africa. Clin. Infect. Dis., 2018, vol. 66, no. 8, pp. 1246-1253. doi: 10.1093/cid/cix1125.Buziashvili M., Davtyan H., Sereda Y., Denisiuk O., Gozalov O., Lomtadze N., Hovhannesyan A. Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018 // Monaldi Arch. Chest Dis. ‒ 2021. ‒ № 91. ‒ Р. 1649.Buziashvili M., Davtyan H., Sereda Y., Denisiuk O., Gozalov O., Lomtadze N., Hovhannesyan A. Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018. Monaldi Arch. Chest Dis., 2021, no. 91, pp. 1649.Chem E. D., Van Hout M. C., Hope V. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in sub Saharan Africa: a systematic review and meta-analysis // BMC Infect. Dis.‒ 2019. ‒ Vol. 19, № 1. ‒ Р. 723.Chem E.D., Van Hout M.C., Hope V. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in sub Saharan Africa: a systematic review and meta-analysis. BMC Infect. Dis., 2019, vol. 19, no. 1, pp. 723.Conradie F., Diacon A. H., Ngubane N., Howell P., Everitt D., Crook A. M., Mendel C. M., Egizi E., Moreira J., Timm J., McHugh T. D., Wills G. H., BatesonA., Hunt R., Van Niekerk C., Li M., Olugbosi M., Spigelman M. Nix-TB Trial Team. Treatment of highly drug-resistant pulmonary tuberculosis // N. Engl. J. Med. ‒ 2020. ‒ Vol. 382, № 10. ‒ Р. 893-902. doi: 10.1056/NEJMoa1901814.Conradie F., Diacon A.H., Ngubane N., Howell P., Everitt D., Crook A.M., Mendel C.M., Egizi E., Moreira J., Timm J., McHugh T.D., Wills G.H., BatesonA., Hunt R., Van Niekerk C., Li M., Olugbosi M., Spigelman M. Nix-TB Trial Team. Treatment of highly drug-resistant pulmonary tuberculosis. N. Engl. J. Med., 2020, vol. 382, no. 10, pp. 893-902. doi: 10.1056/NEJMoa1901814.Dalcolmo M., Gayoso R., Sotgiu G., D'Ambrosio L., Rocha J. L., Borga L., Fandinho F., Braga J. U., Galesi V. M., Barreira D., Sanchez D. A., Dockhorn F., Centis R., Caminero J. A., Migliori G. B. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil // Eur. Respir. J. ‒ 2017. ‒ Vol. 49, № 3. ‒ Р. 1602445. doi: 10.1183/13993003.02445-2016.Dalcolmo M., Gayoso R., Sotgiu G., D'Ambrosio L., Rocha J.L., Borga L., Fandinho F., Braga J.U., Galesi V.M., Barreira D., Sanchez D.A., Dockhorn F., Centis R., Caminero J.A., Migliori G.B. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur. Respir.J., 2017, vol. 49, no. 3, pp. 1602445. doi: 10.1183/13993003.02445-2016.Daniels J. F., Khogali M., Mohr E., Cox V., Moyo S., Edginton M., HinderakerS.G., Meintjes G., Hughes J., De Azevedo V., van Cutsem G., CoxH. S. Time to ART initiation among patients treated for rifampicin-resistant tuberculosis in Khayelitsha, South Africa: impact on mortality and treatment success // PLoS One. ‒ 2015. ‒ Vol. 10, № 11. ‒ Р. e0142873. doi: 10.1371/journal.pone.0142873.Daniels J.F., Khogali M., Mohr E., Cox V., Moyo S., Edginton M., HinderakerS.G., Meintjes G., Hughes J., De Azevedo V., van Cutsem G., Cox H.S. Time to ART initiation among patients treated for rifampicin-resistant tuberculosis in Khayelitsha, South Africa: impact on mortality and treatment success. PLoS One, 2015, vol. 10, no. 11, pp. e0142873. doi: 10.1371/journal.pone.0142873.Edessa D., Sisay M., Dessie Y. Unfavorable outcomes to second-line tuberculosis therapy among HIV-infected versus HIV-uninfected patients in sub-Saharan Africa: A systematic review and meta-analysis // PLoS One. ‒ 2020. ‒ Vol. 15, № 8. ‒ Р. e0237534. doi: 10.1371/journal.pone.0237534.Edessa D., Sisay M., Dessie Y. Unfavorable outcomes to second-line tuberculosis therapy among HIV-infected versus HIV-uninfected patients in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One, 2020, vol. 15, no. 8, pp. e0237534. doi: 10.1371/journal.pone.0237534.Espinosa-Pereiro J., Sánchez-Montalvá A., Aznar M. L., Espiau M. MDR tuberculosis treatment // Medicina (Kaunas). 2022. ‒ Vol. 58, № 2. ‒ Р. 188. doi: 10.3390/medicina58020188.Espinosa-Pereiro J., Sánchez-Montalvá A., Aznar M.L., Espiau M. MDR tuberculosis treatment. Medicina (Kaunas), 2022, vol. 58, no. 2, pp. 188. doi: 10.3390/medicina58020188.Gao J. T., Du J., Wu G. H., Pei Y., Gao M. Q., Martinez L., Fan L., ChenW., XieL., Chen Y., Wang H., Jin L., Li G. B., Zong P. L., Xiong Y., Wu Q.H., LiM.W., YanX.F., Miao Y. F., Cai Q. S., Li X. J., Bai D. P., Geng S. J., YangG.L., TangP.J., Zeng Y., Chen X. H., Li T. X., Cai C., Zhou Y., ZhuoM., WangJ.Y., GuanW.L., XuL., Shi J.C., Shu W., Cheng L. L., Teng F., Ning Y.J., XieS.H., Sun Y. X., ZhangL. J., Liu Y. H. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety // Infect. Dis. Poverty. ‒ 2021. ‒ Vol. 10, № 1. ‒ Р. 32. doi: 10.1186/s40249-021-00819-2.Gao J.T., Du J., Wu G.H., Pei Y., Gao M.Q., Martinez L., Fan L., Chen W., Xie L., Chen Y., Wang H., Jin L., Li G.B., Zong P.L., Xiong Y., Wu Q.H., LiM.W., YanX.F., Miao Y.F., Cai Q.S., Li X.J., Bai D.P., Geng S.J., Yang G.L., Tang P.J., Zeng Y., Chen X.H., Li T.X., Cai C., Zhou Y., Zhuo M., Wang J.Y., GuanW.L., Xu L., Shi J.C., Shu W., Cheng L.L., Teng F., Ning Y.J., Xie S.H., Sun Y.X., ZhangL.J., Liu Y.H. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety. Infect. Dis. Poverty, 2021, vol. 10, no. 1, pp. 32. doi: 10.1186/s40249-021-00819-2.Geiger K., Stamper P. D., Farley J. E. The effects of MDR/RR-TB treatment on HIV disease: A systematic review of literature // PLoS One. ‒ 2021. ‒ Vol. 16, № 3. ‒ Р. e0248174. doi: 10.1371/journal.pone.0248174.Geiger K., Stamper P.D., Farley J.E. The effects of MDR/RR-TB treatment on HIV disease: A systematic review of literature. PLoS One, 2021, vol. 16, no. 3, pp. e0248174. doi: 10.1371/journal.pone.0248174.Hong H., Budhathoki C., Farley J. E. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection // Int. J. Tuberc. Lung Dis. ‒ 2018. ‒ Vol. 22, № 6. ‒ Р. 667-674. doi: 10.5588/ijtld.17.0830.Hong H., Budhathoki C., Farley J.E. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection. Int. J. Tuberc. Lung Dis., 2018, vol. 22, no. 6, pp. 667-674. doi: 10.5588/ijtld.17.0830.Hughes J., Reuter A., Chabalala B., Isaakidis P., Cox H., Mohr E. Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting // Int. J. Tuberc. Lung Dis. ‒ 2019. ‒ Vol. 23, № 9. ‒ Р. 1017-1023. doi: 10.5588/ijtld.18.0651.Hughes J., Reuter A., Chabalala B., Isaakidis P., Cox H., Mohr E. Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting. Int. J. Tuberc. Lung Dis., 2019, vol. 23, no. 9, pp. 1017-1023. doi: 10.5588/ijtld.18.0651.Hurtado R. M., Meressa D., Goldfeld A. E. Treatment of drug-resistant tuberculosis among people living with HIV // Curr. Opin HIV AIDS. ‒ 2018.‒ № 13. ‒ Р. 478-485.Hurtado R.M., Meressa D., Goldfeld A.E. Treatment of drug-resistant tuberculosis among people living with HIV. Curr. Opin HIV AIDS, 2018, no. 13, pp. 478-485.Isaakidis P., Varghese B., Mansoor H., Cox H. S., Ladomirska J., SaranchukP., Da Silva E., Khan S., Paryani R., Udwadia Z., Migliori G. B., Sotgiu G., ReidT. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India // PLoS One. ‒ 2012. ‒ Vol. 7, № 7. ‒ Р. e40781. doi: 10.1371/journal.pone.0040781.Isaakidis P., Varghese B., Mansoor H., Cox H.S., Ladomirska J., SaranchukP., Da Silva E., Khan S., Paryani R., Udwadia Z., Migliori G.B., Sotgiu G., ReidT. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One, 2012, vol. 7, no. 7, pp. e40781. doi: 10.1371/journal.pone.0040781.Jacobs T. Q., Ross A. Adverse effects profile ofmultidrug-resistant tuberculosis treatment in a South African outpatient clinic // South African Fam. Pract. ‒ 2012. ‒ № 54. ‒ Р. 531-539.Jacobs T.Q., Ross A. Adverse effects profile ofmultidrug-resistant tuberculosis treatment in a South African outpatient clinic. South African Fam. Pract., 2012, no. 54, pp. 531-539.Katrak S., Lowenthal P., Shen R., True L., Henry L., Barry P. Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California // J.Clin. Tuberc. Other Mycobact. Dis. 2021. ‒ № 23. ‒ Р. 100216. doi: 10.1016/j.jctube.2021.100216.Katrak S., Lowenthal P., Shen R., True L., Henry L., Barry P. Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. J.Clin. Tuberc. Other Mycobacter. Dis., 2021, no. 23, pp. 100216. doi: 10.1016/j.jctube.2021.100216.Kelly A. M., Smith B., Luo Z. et al. Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment // Int. J. Tuberc. Lung Dis.‒ 2016. ‒ № 20. ‒ Р. 442-447.Kelly A.M., Smith B., Luo Z. et al. Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment. Int. J. Tuberc. Lung Dis., 2016, no. 20, pp. 442-447.Khan P. Y., Yates T. A., Osman M., Warren R. M., van der Heijden Y., Padayatchi N., Nardell E. A., Moore D., Mathema B., Gandhi N., Eldholm V., Dheda K., Hesseling A. C., Mizrahi V., Rustomjee R., Pym A. Transmission of drug-resistant tuberculosis in HIV-endemic settings // Lancet Infect Dis. ‒ 2019. ‒ Vol. 19, № 3. ‒ Р. e77-e88. doi: 10.1016/S1473-3099(18)30537-1.Khan P.Y., Yates T.A., Osman M., Warren R.M., van der Heijden Y., PadayatchiN., Nardell E.A., Moore D., Mathema B., Gandhi N., Eldholm V., Dheda K., Hesseling A.C., Mizrahi V., Rustomjee R., Pym A. Transmission of drug-resistant tuberculosis in HIV-endemic settings. Lancet Infect Dis., 2019, vol. 19, no. 3, pp. e77-e88. doi: 10.1016/S1473-3099(18)30537-1.Koirala S., Shah N. P., Pyakurel P., Khanal M., Rajbhandari S. K., Pun T., Shrestha B., Maharjan B., Karki S., Koirala S., Tamang K. B., Roggi A., KumarA.M. V., Ortuño-Gutiérrez N. High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal // Public Health Action. ‒ 2021. ‒ Vol. 11 (Suppl. 1). ‒ Р. 38-45. doi: 10.5588/pha.21.0041.Koirala S., Shah N.P., Pyakurel P., Khanal M., Rajbhandari S.K., Pun T., Shrestha B., Maharjan B., Karki S., Koirala S., Tamang K.B., Roggi A., KumarA.M.V., Ortuño-Gutiérrez N. High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal. Public Health Action, 2021, vol. 11, suppl. 1, pp. 38-45. doi: 10.5588/pha.21.0041.Lan Z., Ahmad N., Baghaei P., Barkane L., Benedetti A., Brode S. K., Brust J. C. M., Campbell J. R., Chang V. W. L., Falzon D., Guglielmetti L., Isaakidis P., Kempker R. R., Kipiani M., Kuksa L., Lange C., Laniado-LaborínR., Nahid P., Rodrigues D., Singla R., Udwadia Z. F., Menzies D. Collaborative group for the meta-analysis of individual patient data in MDR-TB treatment 2017. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis // Lancet Respir. Med. ‒ 2020. ‒ Vol. 8, № 4. ‒ Р. 383-394. doi: 10.1016/S2213-2600(20)30047-3.Lan Z., Ahmad N., Baghaei P., Barkane L., Benedetti A., Brode S.K., BrustJ.C.M., Campbell J.R., Chang V.W.L., Falzon D., Guglielmetti L., Isaakidis P., KempkerR.R., Kipiani M., Kuksa L., Lange C., Laniado-LaborínR., NahidP., Rodrigues D., Singla R., Udwadia Z.F., Menzies D. Collaborative group for the meta-analysis of individual patient data in MDR-TB treatment 2017. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir. Med., 2020, vol. 8, no. 4, pp. 383-394. doi: 10.1016/S2213-2600(20)30047-3.Lazarus G., Tjoa K., Iskandar A. W. B., Louisa M., Sagwa E. L., PadayatchiN., Soetikno V. The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis // PLoS One. ‒ 2021. ‒ Vol. 16, № 3. ‒ Р. e0248017. doi: 10.1371/journal.pone.0248017.Lazarus G., Tjoa K., Iskandar A.W.B., Louisa M., Sagwa E.L., Padayatchi N., Soetikno V. The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis. PLoS One, 2021, vol. 16, no. 3, pp. e0248017. doi: 10.1371/journal.pone.0248017.Lee C. M., Lee E., Bang J. H., Park S. W., Park W. B., Oh M. D., Kim N. J. Prevalence of multidrug-resistant tuberculosis in HIV/tuberculosis co-infected patients // Infect. Chemother. 2021. ‒ Vol. 53, № 4. ‒ Р. 792-795. doi: 10.3947/ic.2021.0085.Lee C.M., Lee E., Bang J.H., Park S.W., Park W.B., Oh M.D., Kim N.J. Prevalence of multidrug-resistant tuberculosis in HIV/tuberculosis co-infected patients. Infect. Chemother., 2021, vol. 53, no. 4, pp. 792-795. doi: 10.3947/ic.2021.0085.Li J., Yang G., Cai Q., Wang Y., Xu Y., Zhang R., Lang Y., Cai X. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis // Int. J. Infect. Dis. ‒ 2021. ‒ № 110. ‒ Р. 179-186. doi: 10.1016/j.ijid.2021.07.038.Li J., Yang G., Cai Q., Wang Y., Xu Y., Zhang R., Lang Y., Cai X. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis. Int. J. Infect. Dis., 2021, no. 110, pp. 179-186. doi: 10.1016/j.ijid.2021.07.038.Mason C. Y., Prieto A., Bogati H., Sannino L., Akai N., Marquardt T. Adverse events using shorter MDR-TB regimens: outcomes from Port Moresby, Papua New Guinea // Public Health Action. ‒ 2021. ‒ Vol. 11, № 1. ‒ Р. 2-4. doi: 10.5588/pha.20.0026.Mason C.Y., Prieto A., Bogati H., Sannino L., Akai N., Marquardt T. Adverse events using shorter MDR-TB regimens: outcomes from Port Moresby, Papua New Guinea. Public Health Action, 2021, vol. 11, no. 1, pp. 2-4. doi: 10.5588/pha.20.0026.Misra N., Padayatchi N., Naidoo P. Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis // S. Afr. Med J. ‒ 2020. ‒ Vol. 110, № 1. ‒ Р. 32-37. doi: 10.7196/SAMJ.2019.v110i1.13954.Misra N., Padayatchi N., Naidoo P. Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis. S. Afr. Med J., 2020, vol. 110, no. 1, pp. 32-37. doi: 10.7196/SAMJ.2019.v110i1.13954.Mohr E., Cox V., Wilkinson L., Moyo S., Hughes J., Daniels J., Muller O., Cox H. Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa // Trans. R. Soc. Trop. Med. Hyg. ‒ 2015. ‒ Vol. 109, № 7. ‒ 425-432. doi: 10.1093/trstmh/trv037.Mohr E., Cox V., Wilkinson L., Moyo S., Hughes J., Daniels J., Muller O., Cox H. Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa. Trans. R. Soc. Trop. Med. Hyg., 2015, vol. 109, no. 7, 425-432. doi: 10.1093/trstmh/trv037.Mohr E., Cox V., Wilkinson L., Moyo S., Hughes J., Daniels J., Muller O., Cox H. Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa // Trans. R. Soc. Trop. Med. Hyg. ‒ 2015. ‒ Vol. 109, № 7. ‒ Р. 425-432. doi: 10.1093/trstmh/trv037.Mohr E., Cox V., Wilkinson L., Moyo S., Hughes J., Daniels J., Muller O., Cox H. Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa. Trans. R. Soc. Trop. Med. Hyg., 2015, vol. 109, no. 7, pp. 425-432. doi: 10.1093/trstmh/trv037.Mohr E., Hughes J., Reuter A., Trivino Duran L., Ferlazzo G., Daniels J., De Azevedo V., Kock Y., Steele S. J., Shroufi A., Ade S., Alikhanova N., Benedetti G., Edwards J., Cox H., Furin J., Isaakidis P. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa // Eur. Respir. J. ‒ 2018. ‒ Vol. 51, № 6. ‒ Р. 1800017. doi: 10.1183/13993003.00017-2018.Mohr E., Hughes J., Reuter A., Trivino Duran L., Ferlazzo G., Daniels J., De Azevedo V., Kock Y., Steele S.J., Shroufi A., Ade S., Alikhanova N., Benedetti G., Edwards J., Cox H., Furin J., Isaakidis P. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. Eur. Respir. J., 2018, vol. 51, no. 6, pp. 1800017. doi: 10.1183/13993003.00017-2018.Monedero-Recuero I., Hernando-Marrupe L., Sánchez-Montalvá A., Cox V., Tommasi M., Furin J., Chiang C. Y., Quelapio M., Koura K. G., Trébucq A., Padanilam X., Dravniece G., Piubello A. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment // Int. J. Tuberc. Lung Dis. ‒ 2018. ‒ Vol. 22, № 12. ‒ Р. 1411-1421. doi: 10.5588/ijtld.18.0423.Monedero-Recuero I., Hernando-Marrupe L., Sánchez-Montalvá A., Cox V., Tommasi M., Furin J., Chiang C.Y., Quelapio M., Koura K.G., Trébucq A., Padanilam X., Dravniece G., Piubello A. QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment. Int. J. Tuberc. Lung Dis., 2018, vol. 22, no. 12, pp. 1411-1421. doi: 10.5588/ijtld.18.0423.Mukonzo J., Aklillu E., Marconi V., Schinazi R. F. Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals // Int. J. Infect. Dis. ‒ 2019. ‒ № 83. ‒ Р. 98-101. doi: 10.1016/j.ijid.2019.04.009.Mukonzo J., Aklillu E., Marconi V., Schinazi R.F. Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals. Int. J. Infect. Dis., 2019, no. 83, pp. 98-101. doi: 10.1016/j.ijid.2019.04.009.Ngoc N. B., Vu Dinh H., Thuy N. T., Quang D. V., Huyen C. T. T., HoaN.M., AnhN. H., Dat P. T., Hoa N. B., Tiemersma E., Nhung N. V. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Vietnam // PLoS One. ‒ 2021. ‒ Vol. 16, №9. ‒ Р. e0255357. doi: 10.1371/journal.pone.0255357.Ngoc N.B., Vu Dinh H., Thuy N.T., Quang D.V., Huyen C.T.T., Hoa N.M., AnhN.H., Dat P.T., Hoa N.B., Tiemersma E., Nhung N.V. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Vietnam. PLoS One, 2021, vol. 16, no. 9, pp. e0255357. doi: 10.1371/journal.pone.0255357.O’Donnell M. R., Padayatchi N., Kvasnovsky C. et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection // Emerg. Infect. Dis. ‒ 2013. ‒ № 19. ‒ Р. 416-424.O’Donnell M.R., Padayatchi N., Kvasnovsky C. et al. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg. Infect. Dis., 2013, no. 19, pp. 416-424.Padayatchi N., Bionghi N., Osman F., Naidu N., Ndjeka N., Master I., BrustJ.C.M., Naidoo K., Ramjee A., O Donnell M. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid // Int. J. Tuberc. Lung Dis. ‒ 2020. ‒ Vol. 24, № 10. ‒ Р. 1024-1031. doi: 10.5588/ijtld.20.0048.Padayatchi N., Bionghi N., Osman F., Naidu N., Ndjeka N., Master I., BrustJ.C.M., Naidoo K., Ramjee A., O Donnell M. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid. Int. J. Tuberc. Lung Dis., 2020, vol. 24, no. 10, pp. 1024-1031. doi: 10.5588/ijtld.20.0048.Sadiq S., Khajuria V., Tandon V. R., Mahajan A., Singh J. B. Adverse Drug Reaction Profile in Patients on Anti-tubercular Treatment Alone and in Combination with Highly Active Antiretroviral Therapy // J. Clin. Diagn. Res.‒ 2015. ‒ Vol. 9, № 10. ‒ FC01-4. doi: 10.7860/JCDR/2015/13452.6652.Sadiq S., Khajuria V., Tandon V.R., Mahajan A., Singh J.B. Adverse Drug Reaction Profile in Patients on Anti-tubercular Treatment Alone and in Combination with Highly Active Antiretroviral Therapy. J. Clin. Diagn. Res., 2015, vol. 9, no. 10, FC01-4. doi: 10.7860/JCDR/2015/13452.6652.Schnippel K., Berhanu R. H., Black A., Firnhaber C., Maitisa N., Evans D., Sinanovic E. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study // BMC Infect. Dis. ‒ 2016. ‒ Vol. 16, № 1. ‒ Р. 593. doi: 10.1186/s12879-016-1933-0.Schnippel K., Berhanu R.H., Black A., Firnhaber C., Maitisa N., Evans D., Sinanovic E. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infect. Dis., 2016, vol. 16, no. 1, pp. 593. doi: 10.1186/s12879-016-1933-0.Schnippel K., Firnhaber C., Berhanu R., Page-Shipp L., Sinanovic E. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis // J. Antimicrob Chemother. ‒ 2017. ‒ Vol. 72, № 7. ‒ Р. 1871-1879. doi: 10.1093/jac/dkx107.Schnippel K., Firnhaber C., Berhanu R., Page-Shipp L., Sinanovic E. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J. Antimicrob Chemother., 2017, vol. 72, no. 7, pp. 1871-1879. doi: 10.1093/jac/dkx107.Schnippel K., Firnhaber C., Berhanu R., Page-Shipp L., Sinanovic E. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa // Int. J. Tuberc. Lung Dis. ‒ 2018. ‒ Vol. 22, № 4. ‒ Р. 393-398. doi: 10.5588/ijtld.17.0661.Schnippel K., Firnhaber C., Berhanu R., Page-Shipp L., Sinanovic E. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. Int. J. Tuberc. Lung Dis., 2018, vol. 22, no. 4, pp. 393-398. doi: 10.5588/ijtld.17.0661.Shin S. S., Modongo C., Boyd R., Caiphus C., Kuate L., Kgwaadira B., ZetolaN.M. High treatment success rates among HIV-infected multidrug-resistant tuberculosis patients after expansion of antiretroviral therapy in Botswana, 2006-2013 // J. Acquir. Immune Defic. Syndr. ‒ 2017. ‒ Vol. 74, № 1. ‒ Р. 65-71. doi: 10.1097/QAI.0000000000001169.Shin S.S., Modongo C., Boyd R., Caiphus C., Kuate L., Kgwaadira B., ZetolaN.M. High treatment success rates among HIV-infected multidrug-resistant tuberculosis patients after expansion of antiretroviral therapy in Botswana, 2006-2013. J. Acquir. Immune Defic. Syndr., 2017, vol. 74, no. 1, pp. 65-71. doi: 10.1097/QAI.0000000000001169.Smith J. P., Gandhi N. R., Shah N. S., Mlisana K., Moodley P., Johnson B. A.etal. The impact of concurrent antiretroviral therapy and MDR-TB treatment on adverse events // J. Acquir Immune Defic. Syndr. ‒ 2020. ‒ № 83. ‒ Р. 47-55. https://doi.org/10.1097/QAI.0000000000002190.Smith J.P., Gandhi N.R., Shah N.S., Mlisana K., Moodley P., Johnson B.A.etal. The impact of concurrent antiretroviral therapy and MDR-TB treatment on adverse events. J. Acquir Immune Defic. Syndr., 2020, no. 83, pp. 47-55. https://doi.org/10.1097/QAI.0000000000002190.Stephens F., Gandhi N. R., Brust J. C. M., Mlisana K., Moodley P., Allana S., Campbell A., Shah S. Treatment adherence among persons receiving concurrent multidrug-resistant tuberculosis and HIV treatment in KwaZulu-Natal, South Africa // J. Acquir. Immune Defic. Syndr. ‒ 2019. ‒ Vol. 82, № 2. ‒ Р. 124-130. doi: 10.1097/QAI.0000000000002120.Stephens F., Gandhi N.R., Brust J.C.M., Mlisana K., Moodley P., Allana S., Campbell A., Shah S. Treatment adherence among persons receiving concurrent multidrug-resistant tuberculosis and HIV treatment in KwaZulu-Natal, South Africa. J. Acquir. Immune Defic. Syndr., 2019, vol. 82, no. 2, pp. 124-130. doi: 10.1097/QAI.0000000000002120.Tack I., Dumicho A., Ohler L., Shigayeva A., Bulti A. B., White K., Mbatha M., Furin J., Isaakidis P. Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A retrospective cohort analysis // Clin. Infect. Dis. ‒ 2021. ‒ Vol. 73, № 9. ‒ Р. e3563-e3571. doi: 10.1093/cid/ciaa1894.Tack I., Dumicho A., Ohler L., Shigayeva A., Bulti A.B., White K., Mbatha M., Furin J., Isaakidis P. Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A retrospective cohort analysis. Clin. Infect. Dis., 2021, vol. 73, no. 9, pp. e3563-e3571. doi: 10.1093/cid/ciaa1894.Van den Hof S., Tursynbayeva A., Abildaev T., Adenov M., Pak S., IsmailovS. HIV and multidrug-resistant tuberculosis: overlapping risk factors // Eur. Resp.J. ‒ 2013. ‒ Vol. 45, № 2. ‒ Р. 567-569.Van den Hof S., Tursynbayeva A., Abildaev T., Adenov M., Pak S., Ismailov S. HIV and multidrug-resistant tuberculosis: overlapping risk factors. Eur. Resp. J., 2013, vol. 45, no. 2, pp. 567-569.Waters R., Ndengane M., Abrahams M. R., Diedrich C. R., WilkinsonR.J., Coussens A. K. The Mtb-HIV syndemic interaction: why treating M.tuberculosis infection may be crucial for HIV-1 eradication // Future Virol. ‒ 2020. ‒ Vol. 15, № 2. ‒ Р. 101-125. doi: 10.2217/fvl-2019-0069.Waters R., Ndengane M., Abrahams M.R., Diedrich C.R., Wilkinson R.J., Coussens A.K. The Mtb-HIV syndemic interaction: why treating M. tuberculosis infection may be crucial for HIV-1 eradication. Future Virol., 2020, vol. 15, no. 2, pp. 101-125. doi: 10.2217/fvl-2019-0069.Wong K., Nguyen J., Blair L., Banjanin M., Grewal B., Bowman S., Boyd H., Gerstner G., Cho H. J., Panfilov D., Tam C. K., Aguilar D., VenketaramanV. Pathogenesis of human immunodeficiency virus-mycobacterium tuberculosis co-infection // J. Clin. Med. ‒ 2020. ‒ Vol. 9, № 11. ‒ Р. 3575. doi: 10.3390/jcm9113575.Wong K., Nguyen J., Blair L., Banjanin M., Grewal B., Bowman S., Boyd H., Gerstner G., Cho H.J., Panfilov D., Tam C.K., Aguilar D., Venketaraman V. Pathogenesis of human immunodeficiency virus-mycobacterium tuberculosis co-infection. J. Clin. Med., 2020, vol. 9, no. 11, pp. 3575. doi: 10.3390/jcm9113575.

The authors declare that there are no conflicts of interest present.